Nexalis Therapeutics Limited (ASX:NX1)
Australia · Delayed Price · Currency is AUD 0.0090
-0.0010 (-10.00%)
At close: Sep 18, 2026
Nexalis Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.79 | 0.44 | 0.19 | 0.72 | 2.13 | 2.8 |
Cash & Short-Term Investments | 0.79 | 0.44 | 0.19 | 0.72 | 2.13 | 2.8 |
Cash Growth | 64.41% | 124.15% | -72.77% | -66.45% | -23.90% | 63.04% |
Other Receivables | 0.73 | 0.91 | 0.45 | 0.8 | 0.03 | 0.02 |
Receivables | 0.73 | 0.91 | 0.45 | 0.8 | 0.03 | 0.02 |
Inventory | - | - | - | - | - | 0.02 |
Prepaid Expenses | 0.09 | 0.08 | 0.07 | 0.06 | 0.08 | 0.06 |
Other Current Assets | - | - | - | - | - | 0 |
Total Current Assets | 1.61 | 1.43 | 0.71 | 1.58 | 2.24 | 2.91 |
Property, Plant & Equipment | 0.01 | - | - | - | - | 0.01 |
Other Intangible Assets | - | - | - | - | 0.01 | 0.01 |
Total Assets | 1.63 | 1.43 | 0.71 | 1.58 | 2.26 | 2.93 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.44 | 1.46 | 0.57 | 0.18 | 0.12 | 0.07 |
Accrued Expenses | 0.01 | 0 | - | 0 | 0 | - |
Short-Term Debt | - | - | - | 0.56 | - | - |
Current Portion of Long-Term Debt | 0.72 | 0.43 | 0.03 | - | - | - |
Current Unearned Revenue | - | - | - | - | - | 0.02 |
Other Current Liabilities | 0.32 | 0.18 | 0.17 | 0.17 | 0.23 | 0.16 |
Total Current Liabilities | 3.49 | 2.07 | 0.78 | 0.91 | 0.36 | 0.25 |
Long-Term Debt | - | 0.32 | - | - | - | - |
Pension & Post-Retirement Benefits | 0 | 0 | 0 | 0 | - | - |
Total Liabilities | 3.49 | 2.38 | 0.78 | 0.91 | 0.36 | 0.25 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 15.39 | 15.15 | 14.53 | 14.08 | 13.93 | 12.9 |
Retained Earnings | -17.3 | -16 | -14.38 | -13.17 | -11.73 | -9.25 |
Comprehensive Income & Other | 0.04 | -0.1 | -0.21 | -0.24 | -0.3 | -0.97 |
Shareholders' Equity | -1.86 | -0.95 | -0.06 | 0.67 | 1.9 | 2.68 |
Total Liabilities & Equity | 1.63 | 1.43 | 0.71 | 1.58 | 2.26 | 2.93 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.72 | 0.74 | 0.03 | 0.56 | - | - |
Net Cash (Debt) | 0.07 | -0.3 | 0.16 | 0.16 | 2.13 | 2.8 |
Net Cash Growth | -50.89% | - | 3.41% | -92.71% | -23.90% | 63.04% |
Net Cash Per Share | 0.00 | -0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
Filing Date Shares Outstanding | 253.04 | 239.36 | 213.45 | 189.77 | 187.27 | 168.47 |
Total Common Shares Outstanding | 253.04 | 239.36 | 213.45 | 189.77 | 187.27 | 168.47 |
Working Capital | -1.88 | -0.63 | -0.06 | 0.67 | 1.89 | 2.65 |
Book Value Per Share | -0.01 | -0.00 | -0.00 | 0.00 | 0.01 | 0.02 |
Tangible Book Value | -1.86 | -0.95 | -0.06 | 0.67 | 1.89 | 2.66 |
Tangible Book Value Per Share | -0.01 | -0.00 | -0.00 | 0.00 | 0.01 | 0.02 |